Meta-analysis of genotype and phenotype studies of RNF213 p.R4810K in moyamoya disease

Takeaway

  • The homozygous or heterozygous RNF213 may be an efficient biomarker for classification of different clinical phenotypes of moyamoya disease (MMD).

Why this matters

  • MMD (an idiopathic cerebrovascular disease) is the main cause of childhood and adolescent stroke in East Asian countries, can result in irreversible neurological and cognitive deficits, and has been linked to the p.R4810K locus of the RNF213 gene (RNF213 p.R4810K); however, its association with clinical phenotypic variability has not been identified.

  • The potential status of RNF213 p.R4810K as an MMD biomarker has important implications for earlier diagnosis, treatment and consequently, more favorable outcomes for children who display clinical symptoms of MMD.

International Medical Press is a global provider of independent medical education. Its mission is to provide healthcare professionals with high-quality, trusted medical information with the aim of helping optimize patient care.

No responsibility is assumed by International Medical Press for any injury and/or damage to persons or property through negligence or otherwise, or from any use or operation of any methods, products, instructions, or ideas contained in the material herein. Because of rapid advances in the medical sciences, International Medical Press recommends that independent verification of diagnoses and drug dosages should be made. The opinions expressed do not reflect those of International Medical Press or the sponsor. International Medical Press assumes no liability for any material contained herein.